The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop packaging cell lines containing the novel vector and to use these commercially for the contract manufacturing of gene therapeutics.
Scientists at the MHH previously showed that the vector system can be flexibly adapted to various applications and is produced efficiently in cell lines normally used in the production of biopharmaceuticals. Ascenion, the MHH’s exclusive technology transfer partner, facilitated the commercialization of the invention, from the patent application to forging the cooperation and negotiating the licensing agreement.
The MHH vector represents an advancement over conventional vector systems, whose therapeutic efficacy has already been established in many indications. “We have created a new platform with broad applications in gene therapy that offers improved safety to patients and increased cost-effectiveness to developers and healthcare systems,” says Prof. Christopher Baum, Director of the Institute for Experimental Haematology at the MHH. Prof. Baum developed the vector system together with his colleagues Dr Julia Sürth and Dr Dr Axel Schambach, supported in part by funding from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence REBIRTH (from Regenerative Biology to Reconstructive Therapy).
The main areas of application range from introducing therapeutic genes into blood stem cells and lymphocytes in order to correct congenital defects, to improving cellular immunity in cancer and HIV infection. Further cell types and diseases are also being targeted using the new vector system.
Prof. Roland Wagner, Senior Vice President Development at Rentschler Biotechnologie GmbH, emphasizes: “The new vector system complements our spectrum for the development of virus-based biologics used in gene therapy and virotherapy, which, beside Rentschler’s own AAV vector technology, will be made available to our clients for the development of these products.” Rentschler is currently financing further research at the MHH on highly efficient and stable packaging cell lines for retroviral vectors.
Ascenion will continue to assist with the project. “We are delighted that the research findings from the MHH have been developed to the benefit of patients,” commented Dr Christian Stein, Ascenion’s CEO. “The partners complement each other perfectly: the MHH contributes its innovative technology and proximity to patients, and Rentschler contributes its longstanding experience in the production of biopharmaceuticals and its tight industry network.”
Further information at www.ascenion.de
About the Hannover Medical School (MHH)
Hannover Medical School (MHH), founded in 1965, is one of Germany's leading universities in research, patient care and teaching. With its concentrated support of specialised research areas, it has become one of the best university clinics in the country. The outstanding research conducted at Germany's only institution of higher education exclusively devoted to medicine has been clearly recognised within the framework of the Excellence Initiative supported by the federal and state governments.
Further information at www.mh-hannover.de
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years’ experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1000 and 2500 liters, allowing the production of material for clinical trials (Phases I to III) and for market supply, and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Further information at www.rentschler.de
How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
22.01.2018 | Materials Sciences
22.01.2018 | Earth Sciences
22.01.2018 | Life Sciences